ABSTRACT
Phase II trials provide the testing ground for the development of definitive Phase III trials through the screening of new agents for antitumor activity, and by piloting new treatment combinations and schedules. In recent years the focus of Phase II trial design has undergone a substantial shift in emphasis, partially in response to the development of targeted agents, and in part on the popularity of randomized Phase II designs.
